---
figid: PMC6660578__401_2019_2004_Fig4_HTML
figlink: /pmc/articles/PMC6660578/figure/Fig4/
number: Fig. 4
caption: Genetic risk factors and synapse dysfunction in AD pathogenesis. Regulation
  of the focal adhesion pathway plays central roles in synaptic plasticity (synaptic
  maintenance, actin cytoskeleton remodelling, vesicle, and receptor cycling). Dysfunction
  of downstream cellular signalling pathways involving APP and/or Tau may thus participate
  in synapse loss. Additionally, dysregulation of the core FA pathway could modulate
  APP and Tau metabolisms, leading to an exacerbation of synaptotoxicity through Aβ
  overproduction and Tau-modulated excitotoxicity. Finally, Aβ availability at the
  synapses is dependent on its clearance through the blood brain barrier and/or by
  microglial cells
pmcid: PMC6660578
papertitle: 'The new genetic landscape of Alzheimer’s disease: from amyloid cascade
  to genetically driven synaptic failure hypothesis?.'
reftext: Pierre Dourlen, et al. Acta Neuropathol. 2019;138(2):221-236.
pmc_ranked_result_index: '21781'
pathway_score: 0.923152
filename: 401_2019_2004_Fig4_HTML.jpg
figtitle: Genetic risk factors and synapse dysfunction in AD pathogenesis
year: '2019'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6660578__401_2019_2004_Fig4_HTML.html
  '@type': Dataset
  description: Genetic risk factors and synapse dysfunction in AD pathogenesis. Regulation
    of the focal adhesion pathway plays central roles in synaptic plasticity (synaptic
    maintenance, actin cytoskeleton remodelling, vesicle, and receptor cycling). Dysfunction
    of downstream cellular signalling pathways involving APP and/or Tau may thus participate
    in synapse loss. Additionally, dysregulation of the core FA pathway could modulate
    APP and Tau metabolisms, leading to an exacerbation of synaptotoxicity through
    Aβ overproduction and Tau-modulated excitotoxicity. Finally, Aβ availability at
    the synapses is dependent on its clearance through the blood brain barrier and/or
    by microglial cells
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - GRIN2D
  - GRIN3A
  - ACTA1
  - CLU
  - ADAM10
  - ABO
  - PICALM
  - CD3D
  - CD3E
  - APOE
  - CD247
  - PLCG2
  - ACTA2
  - CD3G
  - PTK2B
  - CD2AP
  - PSEN1
  - PSEN2
  - SORL1
  - MAPT
  - TREM2
  - GRIN3B
  - GRIN1
  - GRIN2A
  - GRIN2B
  - APP
  - ASS1
  - BIN1
  - ACTC1
  - ACTG1
  - ACTG2
  - ACTB
  - GRIN2C
  - Oligodendrocyte dysfunction
  - toxicity
genes:
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN2D
  entrez: '2906'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN3A
  entrez: '116443'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTA1
  entrez: '58'
- word: CLU,
  symbol: CLU
  source: hgnc_symbol
  hgnc_symbol: CLU
  entrez: '1191'
- word: ADAM10,
  symbol: ADAM10
  source: hgnc_symbol
  hgnc_symbol: ADAM10
  entrez: '102'
- word: ABo
  symbol: ABO
  source: hgnc_symbol
  hgnc_symbol: ABO
  entrez: '28'
- word: APOE,CRI,CLU,ABCAT,PICALM.
  symbol: PICALM
  source: hgnc_symbol
  hgnc_symbol: PICALM
  entrez: '8301'
- word: APOE,TREM2,ABIS,PLCG2,CD3.
  symbol: CD3
  source: bioentities_symbol
  hgnc_symbol: CD3D
  entrez: '915'
- word: APOE,TREM2,ABIS,PLCG2,CD3.
  symbol: CD3
  source: bioentities_symbol
  hgnc_symbol: CD3E
  entrez: '916'
- word: APOE,CRI,CLU,ABCAT,PICALM.
  symbol: APOE
  source: hgnc_symbol
  hgnc_symbol: APOE
  entrez: '348'
- word: APOE,TREM2,ABIS,PLCG2,CD3.
  symbol: CD3
  source: bioentities_symbol
  hgnc_symbol: CD247
  entrez: '919'
- word: APOE,TREM2,ABIS,PLCG2,CD3.
  symbol: PLCG2
  source: hgnc_symbol
  hgnc_symbol: PLCG2
  entrez: '5336'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTA2
  entrez: '59'
- word: APOE,TREM2,ABIS,PLCG2,CD3.
  symbol: CD3
  source: bioentities_symbol
  hgnc_symbol: CD3G
  entrez: '917'
- word: BIN1,CLU,PICALM,PTK2B.
  symbol: PTK2B
  source: hgnc_symbol
  hgnc_symbol: PTK2B
  entrez: '2185'
- word: CD2AP,
  symbol: CD2AP
  source: hgnc_symbol
  hgnc_symbol: CD2AP
  entrez: '23607'
- word: PSEN1,
  symbol: PSEN1
  source: hgnc_symbol
  hgnc_symbol: PSEN1
  entrez: '5663'
- word: PSEN2,
  symbol: PSEN2
  source: hgnc_symbol
  hgnc_symbol: PSEN2
  entrez: '5664'
- word: SORL1,
  symbol: SORL1
  source: hgnc_symbol
  hgnc_symbol: SORL1
  entrez: '6653'
- word: Tau
  symbol: tau
  source: hgnc_alias_symbol
  hgnc_symbol: MAPT
  entrez: '4137'
- word: TREM2,
  symbol: TREM2
  source: hgnc_symbol
  hgnc_symbol: TREM2
  entrez: '54209'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN3B
  entrez: '116444'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN1
  entrez: '2902'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN2A
  entrez: '2903'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN2B
  entrez: '2904'
- word: APP
  symbol: APP
  source: hgnc_symbol
  hgnc_symbol: APP
  entrez: '351'
- word: Aß
  symbol: ASS
  source: hgnc_prev_symbol
  hgnc_symbol: ASS1
  entrez: '445'
- word: BIN1,CLU,PICALM,PTK2B.
  symbol: BIN1
  source: hgnc_symbol
  hgnc_symbol: BIN1
  entrez: '274'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTC1
  entrez: '70'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTG1
  entrez: '71'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTG2
  entrez: '72'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTB
  entrez: '60'
- word: NMDAR
  symbol: NMDAR
  source: bioentities_symbol
  hgnc_symbol: GRIN2C
  entrez: '2905'
chemicals: []
diseases:
- word: Oligodendrocyte dysfunction
  source: MESH
  identifier: D056784
- word: toxicity
  source: MESH
  identifier: D064420
---
